14.4 Immunosuppressants, Interactions and Patient Teaching

Why Medication Continues

The recipient's immune system can recognize donor tissue as foreign. Immunosuppressants reduce that response but do not eliminate all rejection. Regimens often combine drugs with different mechanisms to balance protection and toxicity. Induction around surgery differs from maintenance treatment, and rescue treatment for rejection is another distinct purpose. The transplant team individualizes the regimen to immunologic risk, adverse effects and graft course.

Patients need to understand that feeling well does not mean the graft no longer needs protection. Medication usually continues while the graft functions, and later reduction or withdrawal requires specialist direction. A nurse should not advise stopping therapy because the creatinine is normal, the patient has an infection or dialysis is no longer required. Those situations require assessment and a coordinated plan.

Calcineurin Inhibitors

Tacrolimus and cyclosporine inhibit calcineurin-dependent T-cell activation. They have a narrow therapeutic range and require timed drug-level monitoring. Toxicity can include kidney injury, hypertension, tremor or other neurologic symptoms, electrolyte abnormalities and metabolic effects. An increased creatinine can reflect toxicity, rejection, dehydration, obstruction or another problem; it is not automatically rejection.

Levels are interpreted in relation to the specific drug, formulation, dose timing and post-transplant phase. A trough sample is obtained before the scheduled dose according to the program's instructions. Do not take the dose first and label the later sample a trough. There is no universal target level for every recipient and every year after transplant. Different tacrolimus formulations are not casually interchangeable; dose changes require the prescriber and pharmacy process.

Antimetabolites and Other Agents

Mycophenolate inhibits lymphocyte purine synthesis and commonly causes GI symptoms and cytopenias. It also has major reproductive risks, so pregnancy planning and required precautions need specialist counseling. Azathioprine has hematologic toxicity and important interactions, notably with xanthine-oxidase inhibitors such as allopurinol; the team must review such combinations. Do not dismiss a new low white-cell count as a harmless dialysis artifact.

mTOR inhibitors such as sirolimus or everolimus have different effects, including dyslipidemia, impaired wound healing, proteinuria and cytopenias in some patients. Belatacept is a supervised infusion option for selected recipients with specific eligibility and safety considerations. The nurse needs to recognize that alternative regimens have their own risks rather than assuming every replacement is safer.

These are broad teaching categories. The actual drug label and transplant protocol define specific actions, doses and contraindications.

Corticosteroids and Infection Risk

Corticosteroids modify immune responses and may be used in maintenance or rejection treatment. They can increase glucose, fluid retention, BP, infection risk and bone complications. Some centers use steroid-minimizing strategies, but patients must not stop them abruptly without guidance. Teach the patient to report hyperglycemia symptoms, infection signs and medication intolerance.

Immunosuppression can blunt fever and other inflammatory findings. New cough, urinary symptoms, diarrhea, unusual fatigue or wound changes deserve prompt advice even without a high temperature. The team may prescribe antimicrobial prophylaxis, but prophylaxis does not exclude infection. Vaccines and exposure precautions follow transplant-specific recommendations; live vaccines generally require particular caution after transplantation.

Interactions and Practical Adherence

Review every prescription, over-the-counter product and supplement. Some azole antifungals, macrolides, calcium-channel blockers and other agents can alter calcineurin-inhibitor concentrations; grapefruit products can also interact. The direction and magnitude depend on the actual drug combination. Do not provide a blanket instruction to double or halve the immunosuppressant. Contact the transplant pharmacist or prescriber.

Develop a practical dosing routine, use accessible medication lists and verify refill arrangements. A missed dose, persistent vomiting or inability to obtain medicine requires prompt program contact for specific instructions. Patients should not automatically double the next dose. Explain what to do during illness and travel and whom to call outside ordinary hours. Address costs and side effects before they cause silent omission.

Scenario and Monitoring

A patient takes tacrolimus before the morning blood draw and the reported 'trough' is unexpectedly high. The nurse identifies the timing error, reports it and follows the program's repeat-sampling plan rather than independently reducing the dose. If the same patient has worsening creatinine and tremor, both the symptoms and valid drug exposure need evaluation. Good medication care joins trustworthy sampling with clinical observation.

Source: KDIGO transplant-recipient care; current product labeling and the patient's transplant protocol govern individual dosing.